1 / 3

ADCC responses arising during acute/early HIV infection do not prevent rapid disease progression

ADCC responses arising during acute/early HIV infection do not prevent rapid disease progression

holden
Download Presentation

ADCC responses arising during acute/early HIV infection do not prevent rapid disease progression

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. ADCC responses arising during acute/early HIV infection do not prevent rapid disease progression María Julia Ruiz 1, Yanina Ghiglione1, María Eugenia Socías3, Natalia Laufer1 2, Pedro Cahn2, 3, Omar Sued3, María Magdalena Gherardi1,Horacio Salomon1, Ana María Rodriguez1, Gabriela Turk1. 1Instituto de Investigaciones Biomédicas en Retrovirus y Sida, Universidad de Buenos Aires/CONICET, Buenos Aires, Argentina. 2 Hospital Juan A. Fernández, Unidad Enfermedades Infecciosas, Buenos Aires, Argentina. 3. FundaciónHuesped, Buenos Aires, Argentina • ADCCis an effector mechanism known to play a relevant role in antiviral immunity. • Data coming from HIV infected EC and humans and monkeys that were vaccinated in indifferent trials suggest that these activities may protect from infection and progression. • However, the role of these antibodies in natural infection is still controversial. INTRODUCTION AIM: To establish the potential role of ADCC-mediating HIV-specific antibodies in the control of acute/early primary HIV infection (PHI) and disease progression M&M • Samples: Plasma from 20 HIV+ PHI subjects (baseline and 12-month samples)10 HAART-naïve chronically infected patients (C) and 7 Elite Controllers (EC). UncoatedCoated • ADCC assay: ADCC was analyzed using the rapid and flourometric ADCC assay (RFADCC, V.R. Gómez-Román et al. / Journal of Immunological Methods 308 (2006) 53–67 ) which relies on PKH-26 and CFSE staining of gp120-coated target cells (CEM–NKR) before the addition of subject’s plasma and effectors cells (PBMCs from healthy donors). Percentage of ADCC-killing and ADCC titers were determined. PHI>350 cells/ml“Non-progressors” PHI all PHI<350 cells/ml“Progressors” 53.1 % 9,6 %

  2. ADCC Responses in phi subjects , chronicallyinfectedpatients and elite controllers ADCC Responses and DiseaseProgression

  3. CONCLUSIONS • ADCC responses arose earlyafter infection and increased during the first year post-infection in untreated patients • The initiation of HAART during the first year post-infection modifies ADCC responses • No association was found between the magnitude of ADCC responses and the evolution of acute infection or early disease progression ACKNOWLEDGMENTS • María Eugenia Socías • Omar Sued • Pedro Cahn • María Julia Ruiz • YaninaGhiglione • Natalia Laufer • Maria Magdalena Gherardi • Horacio Salomon • Ana MariaRodriguez • Gabriela Turk Grupo Argentino de Seroconversión StudyGroup

More Related